[ad_1] Safety and mortality results in the Intrepid trial at one-year The study evaluated 33 patients enrolled in the early feasibility trial, focusing on safety and mortality outcomes. Zahr reported…
Tag: Transcatheter Cardiovascular Therapeutics (TCT)
TAVR or SAVR? Where things stand now, from a surgeon’s perspective
[ad_1] While the 5-year results of the PARTNER 3 Low-Risk trial and the 4-year results from the Evolut Low-Risk trial both showed excellent results for TAVR, Grubb said the real…
TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial
[ad_1] Details of the WATCH-TAVR trial The WATCH-TAVR trial’s primary endpoint was a composite of all-cause mortality, stroke, and major/life-threatening bleeding over a two-year period. Results of the trial revealed…
TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial
[ad_1] Steven Yakubov, MD, director of the MidWest Cardiology Research Foundation at OhioHealth Riverside Methodist Hospital, looked at overall valve performance for this study. This included structural valve deterioration, non-structural…